ANNX Company Profile and Key Details
NASDAQ : ANNX
Annexon
$5.10
0.04+0.79%
At Close 4:00 PM59.21
BESG ScoreESG Rating
Price Chart
Stock Price Today
Annexon, Inc. (ANNX) stock surged +0.79%, trading at $5.10 on NASDAQ, up from the previous close of $5.06. The stock opened at $5.04, fluctuating between $5.00 and $5.19 in the recent session.
Stock Snapshot
5.06
Prev. Close
609.93M
Market Cap
5
Day Low
-3.62
P/E Ratio
-1.41
EPS (TTM)
-1.55
Cash Flow per Share
5.04
Open
119.6M
Number of Shares
5.19
Day High
81.05%
Free Float in %
3.2
Book Value
1.36M
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Feb 19, 2026 | 5.15 | 5.19 | 5.00 | 5.10 | 1.39M |
| Feb 18, 2026 | 4.98 | 5.18 | 4.93 | 5.06 | 1.86M |
| Feb 17, 2026 | 4.89 | 5.11 | 4.79 | 5.04 | 2.05M |
| Feb 13, 2026 | 5.22 | 5.37 | 4.87 | 4.89 | 1.86M |
| Feb 12, 2026 | 5.25 | 5.44 | 5.13 | 5.19 | 2.21M |
| Feb 11, 2026 | 5.66 | 5.75 | 5.09 | 5.24 | 2.49M |
| Feb 10, 2026 | 5.70 | 5.79 | 5.57 | 5.61 | 3.31M |
| Feb 09, 2026 | 5.71 | 5.71 | 5.46 | 5.63 | 1.72M |
| Feb 06, 2026 | 5.79 | 5.86 | 5.58 | 5.73 | 2.06M |
| Feb 05, 2026 | 5.93 | 6.21 | 5.43 | 5.63 | 2.38M |
| Feb 04, 2026 | 6.42 | 6.52 | 5.90 | 6.04 | 1.88M |
| Feb 03, 2026 | 6.36 | 6.59 | 6.30 | 6.48 | 1.24M |
| Feb 02, 2026 | 6.13 | 6.55 | 6.10 | 6.38 | 1.57M |
| Jan 30, 2026 | 6.65 | 6.84 | 6.16 | 6.24 | 1.79M |
| Jan 29, 2026 | 6.41 | 6.55 | 6.30 | 6.52 | 1.29M |
| Jan 28, 2026 | 6.63 | 6.63 | 6.26 | 6.29 | 3.74M |
| Jan 27, 2026 | 6.66 | 6.82 | 6.49 | 6.57 | 2.45M |
| Jan 26, 2026 | 6.70 | 6.75 | 6.42 | 6.66 | 1.71M |
| Jan 23, 2026 | 6.98 | 7.18 | 6.76 | 6.78 | 2.34M |
| Jan 22, 2026 | 6.87 | 7.06 | 6.86 | 6.96 | 2.78M |
Contact Details
About Company
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barr� syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Company Information
| Employees | 106 |
| Beta | 1.14 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
ARGX
1.91+0.23%
argenx SE$847.26REGN-9.78-1.23%
Regeneron Pharmaceuticals, Inc.$782.38UTHR4.47+0.94%
United Therapeutics Corporation$480.52VRTX-1.04-0.22%
Vertex Pharmaceuticals Incorporated$469.27MDGL-54.62-11.11%
Madrigal Pharmaceuticals, Inc.$436.87ALNY6.69+2.01%
Alnylam Pharmaceuticals, Inc.$339.37PRAX2.68+0.81%
Praxis Precision Medicines, Inc.$331.61KRTX0.09+0.03%
Karuna Therapeutics, Inc.$329.83KRYS-20.62-7.28%
Krystal Biotech, Inc.$262.67ASND3.38+1.49%
Ascendis Pharma A/S$230.21Company Overview
Annexon, Inc. (NASDAQ:ANNX) closed at $5.10 USD, gaining $0.04 (0.79%) from the previous close of $5.06. The stock is currently mid-range between its 52-week high and low $1.28 and $7.18. With a market capitalization of about $609.93 million, Annexon, Inc. is classified as a small-cap and shows market-like volatility (beta ~1.14). Key stats such as the average daily volume over the past year has been around 2.88 million shares, volume is running light vs its 52-week average. Headquartered in Brisbane, CA, Annexon, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Douglas E. Love, the company employs approximately 106 people and listed since July 24, 2020. Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders.
Technical Performance
ANNX has shown sold momentum, gaining 10.79% over the past week and 95.56% over the past quarter, though year-to-date performance is up 22.71%. Short-term trend indicators are bearishly aligned (SMA20 -16.62%, SMA50 -8.9%, SMA200 49.33%). The stock’s 14-day RSI is 38.45 (weak momentum), while the ATR of 0.42 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -29.81% below its high and over 292.22% above its low. Average 10-day trading volume of 2.11 million shares is below the 3-month average of 2.79 million, indicating normal recent market interest.
Valuation Metrics
Annexon, Inc. trades at a P/E ratio of -3.71, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 4.75 trading at moderately above to book value. The P/FCF stands at -3.48, also above market averages.
Dividend & Fair Value
Annexon, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.15. This means the shares are trading above this model’s fair value.
Earnings & Analyst Outlook
Annexon, Inc. generated EPS of -$1.41 over the past year. Five-year average earnings growth is -0.09%. Wall Street analysts project EPS growth of 6.92% annually over the next five years. The latest quarter delivered EPS of -$0.37. The next quarter is forecast at -$0.32. Next year's EPS is expected at $3.74. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $27.00 to $14.00. The high target offers 429.41% upside. The low target suggests 174.51% downside. The mean target is $18.00. This offers 252.94% upside. Annexon, Inc. earnings surprise history is a mixed track record. The quarter that ended November 10, 2025, missed forecasts by 8.82%. The prior quarter beat by -5.56%. Over the last six quarters, Apple has recorded several small beats. These include -99.9% in August 12, 2024.
Shareholding & Insider Activity
Annexon, Inc. has 149.06 million shares outstanding. The public float is 111.26 million shares, elevated short interest at 13.54% of float. This equals 17.22 million shares. The short ratio is 6.63 days. Institutional investors hold 79.46% of the float. Insiders own 0.33%. Satter Muneer A holds 9.73 million shares, Bain Capital Life Sciences Investors, LLC has 5.70 million shares and Clarus Lifesciences III, L.P. has 2.73 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.
Financial & Profitability Overview
On valuation metrics, Annexon trades at a P/E of -3.71, P/S of 0.00 and P/B of 4.75. The current ratio is 4.42 and quick ratio is 4.42. Debt-to-equity is 0.17, supported by a cash flow-to-debt ratio of -6.55.
Quarterly Financial Highlights
The company ended the quarter with $259.72M in cash and short-term investments, a total debt of $31.36M, and net debt of - $193.76M. Total assets were $297.67M, with equity of $250.56M. Financials further reflected weakness, with operating cash flow of - $121.14M, free cash flow of - $121.34M, and capital expenditures of - $193.00K.
Price Forecast & Outlook
Our AI price prediction model suggests that Annexon, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -19.8%, with price expected at $4.09 by March 04, 2026, within a range of $3.68 to $4.45 3-Month Outlook: Projected rise of 43.73%, reaching $7.33 by May 19, 2026, with a range of $7.16 to $7.53. 1-Year Outlook: Projected gain of 557.06%, with price at $33.51 by February 18, 2027, within a range of $30.66 to $44.13.
Key Takeaways
Annexon, Inc. (NASDAQ:ANNX) shares are up 22.71% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Annexon, Inc. trading at a premium to the broader market with a P/E of -3.71. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $21.54, suggesting 322.35% upside. Our AI forecast model points to short-term weakness (-19.8% over two weeks), a medium-term rise (43.73% over three months), and a longer-term gain (557.06% over one year), with expected trading ranges indicating moderate volatility.
Frequently Asked Questions
What is the current Annexon, Inc. (ANNX) stock price?
Annexon, Inc. (NASDAQ: ANNX) stock price is $5.10 in the last trading session. During the trading session, ANNX stock reached the peak price of $5.19 while $5.00 was the lowest point it dropped to. The percentage change in ANNX stock occurred in the recent session was 0.79% while the dollar amount for the price change in ANNX stock was $0.04.
ANNX's industry and sector of operation?
The NASDAQ listed ANNX is part of Biotechnology industry that operates in the broader Healthcare sector. Annexon, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of ANNX?
Dr. Ted Yednock Ph.D.
Executive Vice President, Chief Innovation Officer & Chairman of the Scientific Advisory Board
Henk-Andre Kroon M.D.
Senior Vice President of Translational Medicine
Mr. Douglas Love J.D., Esq.
Chief Executive Officer, Pres & Director
Dr. Larry C. Mattheakis Ph.D.
Executive Vice President & Chief Scientific Officer
Mr. Michael Overdorf M.B.A.
Executive Vice President & Chief Bus. Officer
Miriam Mason
Senior Vice President of Corporation Communications
Ms. Jennifer Lew
Executive Vice President, Chief Financial Officer & Corporation Sec.
Mr. Douglas Love Esq., J.D.
Chief Executive Officer, Pres & Director
Dr. Dean R. Artis Ph.D.
Chief Scientific Officer & Executive Vice President
Dr. Jamie Dananberg M.D.
Chief Medical Officer
Mirella Villa Del Toro
Sec.
Executive Vice President, Chief Innovation Officer & Chairman of the Scientific Advisory Board
Henk-Andre Kroon M.D.
Senior Vice President of Translational Medicine
Mr. Douglas Love J.D., Esq.
Chief Executive Officer, Pres & Director
Dr. Larry C. Mattheakis Ph.D.
Executive Vice President & Chief Scientific Officer
Mr. Michael Overdorf M.B.A.
Executive Vice President & Chief Bus. Officer
Miriam Mason
Senior Vice President of Corporation Communications
Ms. Jennifer Lew
Executive Vice President, Chief Financial Officer & Corporation Sec.
Mr. Douglas Love Esq., J.D.
Chief Executive Officer, Pres & Director
Dr. Dean R. Artis Ph.D.
Chief Scientific Officer & Executive Vice President
Dr. Jamie Dananberg M.D.
Chief Medical Officer
Mirella Villa Del Toro
Sec.
How ANNX did perform over past 52-week?
ANNX's closing price is 296.89% higher than its 52-week low of $1.29 where as its distance from 52-week high of $7.18 is -28.97%.
How many employees does ANNX have?
Number of ANNX employees currently stands at 106.
Link for ANNX official website?
Official Website of ANNX is: https://www.annexonbio.com
How do I contact ANNX?
ANNX could be contacted at phone 650 822 5500 and can also be accessed through its website. ANNX operates from 1400 Sierra Point Parkway, Brisbane, CA 94005, United States.
How many shares of ANNX are traded daily?
ANNX stock volume for the day was 1.36M shares. The average number of ANNX shares traded daily for last 3 months was 2.88M.
What is the market cap of ANNX currently?
The market value of ANNX currently stands at $609.93M with its latest stock price at $5.10 and 119.6M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep